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University, Taipei, TaiwanA B S T R A C TBackground: Network meta-analysis compares multiple treatments
by incorporating direct and indirect evidence into a general statistical
framework. One issue with the validity of network meta-analysis is
inconsistency between direct and indirect evidence within a loop
formed by three treatments. Recently, the inconsistency issue has
been explored further and a complex design-by-treatment interaction
model proposed. Objective: The aim of this article was to show how
to evaluate the design-by-treatment interaction model using the
generalized linear mixed model. Methods: We proposed an arm-
based approach to evaluating the design-by-treatment inconsistency,
which is ﬂexible in modeling different types of outcome variables. We
used the smoking cessation data to compare results from our arm-
based approach with those from the standard contrast-based
approach. Results: Because the contrast-based approach requires
transformation of data, our example showed that such aee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.10.002
@ntu.edu.tw.
ndence to: Yu-Kang Tu, Department of Public Healt
nal Taiwan University, 17 Xu-Zhou Road, Taipei,transformation may yield biases in the treatment effect and incon-
sistency evaluation, when event rates were low in some treatments.
We also compared contrast-based and arm-based models in the
evaluation of design inconsistency when different heterogeneity
variances were estimated, and the arm-based model yielded more
accurate results. Conclusions: Because some statistical software
commands can detect the collinearity among variables and automati-
cally remove the redundant ones, we can use this advantage to help
with placing the inconsistency parameters. This could be very useful
for a network meta-analysis involving many designs and treatments.
Keywords: generalized linear mixed models, design-by-treatment
interaction, network meta-analysis, randomized controlled trials.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
One recent development in meta-analysis methodology is net-
work meta-analysis for comparisons of multiple treatment groups
[1–8]. Network meta-analysis incorporates all available evidence
into a general statistical framework to yield consistent results for
treatment differences. Network meta-analysis makes a few
assumptions: one is homogeneity; that is, the included studies
for any pair of comparison are similar in their study character-
istics, and this is the same assumption behind the traditional
pairwise meta-analysis; the other is similarity; that is, the
potential confounders and effect modiﬁer are distributed similarly
across different pairwise comparisons across the whole network
[9]. When these assumptions are violated, we may observe
inconsistency in the results between direct and indirect evidence,
posing a potential threat to the validity of network meta-analysis.
The issue of inconsistency within a network meta-analysis
has been discussed from several different perspectives, and
methods have been proposed to evaluate and detect inconsis-
tency [10–14]. Lu and Ades [13] proposed to assess treatmenteffect inconsistency within a loop formed by three treatments in
a network meta-analysis. For instance, for a loop of treatments A,
B, and C, there is potential inconsistency if head-to-head trials
comparing A to B, B to C, or A to C are all available. If the loop is
formed because of a three-arm trial, however, no inconsistency
can be evaluated because the three-arm trial is internally con-
sistent. Dias et al. [14] later proposed a Bayesian node-splitting
model to evaluate the inconsistency between the direct and
indirect evidence. Higgins et al. [12] and White et al. [15] later
proposed a full design-by-treatment model by separating multi-
arm trials from two-arm trials. Suppose head-to-head trials
comparing A to B, B to C, or A to C are all available. For the Lu
and Ades loop inconsistency model, there is only one potential
inconsistency factor in the loop of A-B-C even if a three-arm
design comparing A, B, and C is also included. In contrast, for the
design-by-treatment model, there are three inconsistency
factors because there are four “designs” (three two-arm trial
designs and one three-arm trial design) involved in the loop. It
has been shown that the loop inconsistency model by Lu and
Ades can be viewed as a special case of the design-by-treatmentociety for Pharmacoeconomics and Outcomes Research (ISPOR).
h and Institute of Epidemiology & Preventive Medicine, College of
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pairwise comparison between the two-arm and three-arm trials
[12].
The original design-by-treatment interaction model is formu-
lated on the basis of treatment contrasts of all pairwise compar-
isons within a network meta-analysis. The model with treatment
contrasts as the unit of observation is known as the contrast-
based model or the trial-based model [16–18]. This formulation
gives rise to several inconveniences: ﬁrst, noncontinuous out-
come variables need to be transformed into a continuous varia-
ble; for example, the log odds ratio and the associated standard
error need to be calculated for a binary outcome variable. Second,
a multiarm trial has multiple data entries, and the dependency
within these correlated data needs to be properly taken into
account in the analysis. Third, setting up the potential incon-
sistency factors within a contrast-based network meta-analysis
model that involves many different designs and multiarm trials
could be a tedious task and is prone to errors.
An alternative to the contrast-based model for network meta-
analysis is to use the treatment arm as the unit of observation,
known as the arm-based model [6,17–19]. The aim of this study
was therefore to show how the design-by-treatment interaction
model can be implemented into an arm-based approach to
network meta-analysis within the generalized linear mixed model
framework. We ﬁrst brieﬂy review the design-by-treatment inter-
action model and show how it can be implemented within
generalized linear mixed models using the treatment arm as the
unit of observation, instead of using treatment contrasts. We then
use an example of binary outcome to demonstrate our approach.
Results from our proposed approach are compared with those
from the contrast-based model.
Contrast-Based Design-by-Treatment Interaction Model for
Network Meta-Analysis
In this section, we brieﬂy review the contrast-based design-by-
treatment interaction model, and the details can be found in
the two articles by Higgins et al. [12] and White et al. [15]. The
“design” of a study is the set of treatments compared within the
study, and the design-by-treatment interaction (i.e., design
inconsistency) refers to differences in effect sizes between stud-
ies involving different sets of treatments [12]. The full design-by-
treatment interaction model can be written as follows [12,15]:
μAJdi ¼δAJþβAJdi þωAJd , Model 1
where μdi
AJ is the observed difference in outcome between treat-
ments J and A, such as difference in means for continuous data or
log odds ratio for binary data, in study i within design d; δAJ is the
ﬁxed effect of treatment J relative to treatment A; βdi
AJ is a study-
by-treatment interaction term to estimate the standard hetero-
geneity, that is, variations in the treatment effect for comparison
AJ within studies in design d; and ωd
AJ is a design-by-treatment
interaction term to reﬂect inconsistency (variability between
designs). In model 1, βdi
AJ is treated as random effect, and a
multivariate distribution is assumed when multiarm trials are
involved in the comparisons:
βABdi ,β
AC
di ,…
 TN 0,
X 
The covariance matrix
P
is usually structured by assuming
that all treatment contrasts have the same degree of heterogene-
ity, τ2, and the correlation between random effects is set at 0.5
[13,20,21]. The inconsistency parameter ωd
AJ is modeled as ﬁxed
effect, but its exact number (i.e., its degree of freedom) depends on
the nature of multiarm designs in the network. The degree of
freedom for inconsistency, df inc, is df inc¼
P
d Td1ð ÞðT1Þ, where
Td is the number of treatments in a design d and T is the totalnumber of treatments in the network [15]. For example, suppose a
network meta-analysis consists of two designs with three arms
and six with two arms and compares a total of four treatments;
its df inc is 10 – (4 – 1) ¼ 7. For a network meta-analysis with
many different designs and multiarm trials, however, any param-
eterization requires a very careful tabulation of designs and treat-
ments to locate those identiﬁable ωAJd in the network [12,15].
Arm-Based Design-by-Treatment Interaction Model for
Network Meta-Analysis
In our previous studies, we proposed an arm-based generalized
linear mixed model to implement the Lu and Ades Bayesian
model for network meta-analysis [17,18]. In this section, we
extend our model by incorporating the full design-by-treatment
interaction. In a network with study 1, 2, …, to p, and treat-
ments A, B, …, K, the generalized linear mixed model with
treatment arms as the unit of observation can be written as
follows:
g y^ij
 
¼
Xp
j¼1 bjstudyjþ
XK
k¼B dAktkþ
XK
k¼A γkjtk, Model 2
where g(.) is the link function in the model, y^ij is the estimated
outcome for each arm i in study j, and b1 to bp are regression
coefﬁcients for dummy variables study1 to studyp, respectively.
Variables tk, k ¼ A to K, are dummy variables where treatment k is
coded 1 and the other treatments are coded 0. We use treatment
A as the reference group for the whole network, and tA is
therefore excluded from model 2; consequently, dAk, the regres-
sion coefﬁcient for tk , is the estimated average difference
between treatment A and k. In model 2, γAj to γKj are random
effects for treatment A to K, respectively, and these random
effects (i.e., heterogeneities in treatment effects across studies)
follow a multivariate normal distribution:
γAj
γBj
⋮
γKj
0
BBBBB@
1
CCCCCA
 0,
σ2
0
0
σ2
… 0
… 0
⋮ ⋮ ⋱ ⋮
0 0 … σ2
0
BBBB@
1
CCCCA
0
BBBBB@
1
CCCCCA
Our previous study [17] shows that to estimate the variance σ2
correctly, dummy variables tk need to be centered; otherwise, σ2
tends to be underestimated.
Suppose there are q designs within our network meta-analysis,
resulting in ðq1Þ  ðK1Þ interaction terms that are introduced to
model 2 to obtain the full design-by-treatment model:
g y^ij
 
¼
Xp
j¼1 bjstudyjþ
XK
k¼B dAktkþ
XK
k¼A γkjtkþ
Xq1
i¼1
XK
k¼B ωikdesigni  tk,,
Model 3
where designi  tk, i ¼ 1 to q – 1 and k ¼ B to K, are the product
interaction terms between designi (dummy variable in which
studies within the same design i are coded 1 and those of
different designs coded 0) and tk, and ωik is the estimated
design-by-treatment inconsistency. Note that not all the inter-
action terms in model 3 can be estimated, and the number of
estimable interactions is the degree of freedom for inconsistency,
df inc, discussed in the previous section.
Example Data
The example data set contains results of 24 trials investigating
treatments to help with smoking cessation. This data set has
previously been investigated by Higgins et al. [12], Lu and Ades
[13], and Hasselblad [22]. Table 1 shows how data are organized
for the arm-based analysis. Note that there are some small
Table 1 – Data format for arm-based network meta-
analysis.
Study r n Design Treatment
1 9 140 ACD A
1 23 140 ACD C
1 10 138 ACD D
2 11 78 BCD B
2 12 85 BCD C
2 29 170 BCD D
3 79 702 AB A
3 77 694 AB B
4 18 671 AB A
4 21 535 AB B
5 8 116 AB A
5 19 149 AB B
6 75 731 AC A
6 363 714 AC C
7 2 106 AC A
7 9 205 AC C
8 58 549 AC A
8 237 1561 AC C
9 0 33 AC A
9 9 48 AC C
10 3 100 AC A
10 31 98 AC C
11 1 31 AC A
11 26 95 AC C
12 6 39 AC A
12 17 77 AC C
13 95 1107 AC A
13 134* 1031 AC C
14 15 187 AC A
14 36 504 AC C
15 78 584 AC A
15 73 675 AC C
16 69 1177 AC A
16 54 888 AC C
17 64 642 AC A
17 107 761 AC C
18 5 62 AC A
18 8 90 AC C
19 20 234 AC A
19 34 237 AC C
20 0 20 AD A
20 9 20 AD D
21 20 49 BC B
21 16 43 BC C
22 7 66 BD B
22 32 127 BD D
23 12 76 CD C
23 20 74 CD D
24 9 55 CD C
24 3 26 CD D
Notes. Variable r is the number of smoking cessations, n is the total
number of patients in each treatment group, “design” is the
designs in the network, and “treatment” is the treatment groups
in each trial.
* In Hasselblad [22], it was 143.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 0 – 1 1 2 51122discrepancies in the data (see the footnote for Table 1) presented
by the previous three analyses, and throughout this study we
used the data presented in Higgins et al. [12]. These discrepancies
yield, nevertheless, negligible differences in results. The 24 trialsare grouped into eight designs and compare a total of four
treatments: A is no contact, B self-help, C individual counseling,
and D group counseling. The degree of freedom for the design-by-
treatment inconsistency parameters is 7, and we used the same
treatment ordering ABCD and the order of design as Higgins et al.
did, and the whole data are presented in Table 1.
Contrast-based Design-by-Treatment Interaction Mode
To undertake the contrast-based design-by-treatment interaction
model proposed by Higgins et al. [12], we need to calculate log
odds ratio and its standard error for each treatment contrast
within the same trial using treatment A as the reference treat-
ment. Two issues, however, need to be resolved ﬁrst: one is zero
cells in treatment A of two trials, that is, no one successfully quit
smoking at the end of the trial; and the other is that treatment A
was not included by all trials. Following the approach by White
[23] and Higgins et al. [12], we undertook continuity correction by
adding 0.5 to the zero cell and 1 to the total number of patients in
that treatment group, respectively, and performed data augmen-
tation to trials in which A was not tested by supplying them a
treatment A with a very small total number of patients, for
example, 0.0001 with an average rate of successful smoking
cessation of observed treatment A. Table 2 presents the results
of the consistency model for network meta-analysis and the
design-by-treatment interaction inconsistency model using the
statistical software Stata command mvmeta with the restricted
maximum likelihood estimation algorithms [23]. As noted by
Higgins et al. [12], none of the inconsistency parameters is statisti-
cally signiﬁcant, and results from the global chi-square test for the
seven inconsistency parameters are also nonsigniﬁcant.
Arm-based Design-by-Treatment Interaction Model using
Generalized Linear Mixed Model
To use the arm-based design-by-treatment interaction model, we
can either calculate log odds for each treatment arm and its
standard error to undertake the analysis using the linear mixed
model, or use the original data to undertake the analysis using
the generalized linear mixed model. The latter should provide
more accurate results because the analysis is modeled on the
exact likelihood and no continuity correction is needed for zero
cells. So we present results only from generalized linear mixed
models. For our example data, there are eight designs and four
treatments, so in total there are 7 3¼21 design-by-treatment
interaction terms; however, only 7 of them are identiﬁable owing
to perfect collinearity among dummy variables for study, treat-
ment, and design-by-treatment interaction; so the degree of
freedom for inconsistency is 7.
For instance, in Table 2, only study 2 used design BCD, and the
dummy variable study2 and the 3 interaction terms,
tB  designBCD, tC  designBCD, and tD  designBCD, in model 3 are
therefore perfectly collinear. Consequently, one of the four
variables has to be removed from the model. In some software
packages, such as Stata (version 14, StataCorp, College Station, TX)
commands binreg for generalized linear models and meqrlogit for
generalized linear mixed model, the last of the collinear variables
appearing in the command line will be omitted automatically; that is,
if these four variables appear in the following order:
study2 tB  designBCD tC  designBCD tD  designBCD,
the variable tD  designBCD will be omitted. If we put study2 as the
last variable, the three interaction terms will be kept in the
model, whereas study2 is omitted. The dummy variables studyj in
model 3 have a straightforward interpretation: they represent the
estimated speciﬁc study effects, so we recommend that they be
kept in the model. Higgins et al. [12] recommended placing the
design-by-treatment inconsistency parameter in a reverse order,
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 0 – 1 1 2 5 1123that is, placing the parameter on the last treatment in a design
ﬁrst, and then the second last treatment, and so on. For example,
for design BCD, the inconsistency parameter is ﬁrst placed on
treatment D and then on treatment C, and this means that the
recommended order for the four variables study2, tB  designBCD,
tC  designBCD, and tD  designBCD is as follows:
study2 tD  designBCD tC  designBCD tB  designBCD ̇
The last variable tB  designBCD will be automatically omitted
owing to perfect collinearity. In the full design-by-treatment
interaction model, the appearance of variables should therefore
be in the following order: dummy variables for treatments,
dummy variables for study effect, design-by-treatment interac-
tion for the last treatment in the network, design-by-treatment
interaction for the second last treatment in the network, …,
design-by-treatment interaction for the second treatment in the
network.
Table 2 also presents the results of the consistency model and
the full design-by-treatment inconsistency model using Stata
command meqrlogit. Compared with results from contrast-
based consistency models, the arm-based consistency model
showed greater difference between treatment A and the other
three treatments. This is probably owing to adding 0.5 to the two
zero cells of treatment A in the contrast-based model, which gave
rise to an overestimated treatment effect of A. Note that the
estimated random effect variance (i.e., heterogeneity) in the arm-
based analysis is about half of that in the contrast-based analysis,
and this is because the arm-based analysis estimates the hetero-
geneity among different treatments, whereas the contrast-based
model estimates the heterogeneity among different treatment
contrasts.
Most results from the arm-based inconsistency model are
very similar to those from contrast-based inconsistency models.
The main difference is in the effect of design AD by treatment D
interaction. Design AD consists of only one study (study 20 in
Table 1), and its treatment A contains no case of successful
smoking cessation. Because contrast-based analysis added 0.5 to
zero cells, it overestimated the treatment effect for A and
consequently underestimated the difference between treatment
A and D. The design AD by treatment D interaction effect is the
difference in treatment effect of D relative to A between study 20
and study 1 (the reference design ACD), and therefore, the arm-
based analysis gave rise to a larger interaction effect with a
greater conﬁdence interval owing to the zero cell count than that
in the contrast-based analysis with continuity correction.Arm-based Network Meta-Analysis Model with Different
Heterogeneities across Treatments
In the previous analyses, both the contrast-based and arm-based
models assume a common heterogeneity variance for the
treatment-by-study interaction, that is, τ2 in model 1 and σ2 in
model 2. If we wish to estimate individual heterogeneity variances
for each treatment, the variance-covariance structure for hetero-
geneity in contrast-based models becomes quite complex. With
the data augmentation approach, we still need to estimate
kðk1Þ=2 variance and covariance parameters. The model might
not be able to converge, and the computation speed would be very
slow for a large network. In contrast, the number of parameters
for variances and covariances to be estimated in the arm-based
model is k. For our example data, the arm-based generalized
linear mixed model shows that treatment contrast AC seems to
have the largest heterogeneity, whereas treatment contrast AB
has the smallest one (Table 3). After the design-by-treatment
interactions are included in the model, the heterogeneity in
treatment contrasts AB and AD is no longer detectable. For the
contrast-based model with an unstructured variance-covariance,
Table 3 – Results from the consistent and the full design-by-treatment interaction contrast-based linear mixed
model by Higgins et al. and from the proposed arm-based generalized linear mixed model.
Model
parameters
Contrast-based linear mixed model Arm-based generalized linear mixed model
Consistency model
Design-by-
treatment
interaction model
Consistency model
Design-by-treatment
interaction model
Coef. SE P Coef. SE P Coef. SE P Coef. SE P
tAB 0.33 0.30 0.275 0.23 0.25 0.356 0.30 0.30 0.318 0.14 0.14 0.325
tAC 0.68 0.22 0.002 1.05 0.92 0.253 0.75 0.20 o0.001 1.04 0.79 0.187
tAD 0.84 0.37 0.023 0.13 1.32 0.923 0.95 0.35 0.006 0.13 0.48 0.787
tBC 0.35 0.35 0.487 0.82 0.95 0.551 0.45 0.32 0.162 0.90 0.80 0.261
tBD 0.51 0.36 0.300 0.10 1.34 0.796 0.65 0.37 0.075 0.01 0.50 0.982
tCD 0.16 0.37 0.726 0.92 0.84 0.441 0.21 0.36 0.567 0.91 0.78 0.243
tAC  designAC 0.33 0.95 0.729 0.28 0.82 0.729
tAC  designBC 0.97 1.38 0.484 1.06 1.13 0.351
tAC  designBCD 0.82 1.39 0.554 0.91 1.14 0.423
tAD  designAD 3.40 2.34 0.147 16.72 376.36 0.965
tAD  designBCD 0.33 1.86 0.861 0.24 0.63 0.706
tAD  designBD 1.14 1.88 0.543 1.05 0.67 0.115
tAD  designCD 1.22 0.86 0.154 1.16 0.99 0.241
Heterogeneity
variance
tAB 0.314 0.233 0.243 3.44  105
tAC 0.750 0.821 0.808 0.674
tAD 0.723 1.229 0.668 2.97  105
Correlation
tAB-tAC 0.936 0.226
tAB-tAD 0.856 0.063
tAC-tAD 0.620 0.958
Notes. No common heterogeneity is assumed. tAB, tAC, and tAD are treatment contrast between A and B, C, and D, respectively. designAC
represents studies including treatments A and C and the same applies to other variables for “design.” Variances of tAB, tAC, and tAD are derived
from the variances of centered dummy variables for the four treatments tA, tB, tC, and tD.
Coef:, regression coefﬁcient; SE, standard error.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 0 – 1 1 2 51124the heterogeneities seem to be overestimated, because even with
the adjustment of design inconsistency, there seem to be hetero-
geneities in all three treatment contrasts (Table 3).
Complete Stata codes and output for all the analyses for
network meta-analysis in this article can be found in the
Appendix in Supplemental Material found at http://dx.doi.org/%
2010.1016/j.jval.2015.10.002.Discussion
In this article, we showed how to evaluate the design-by-
treatment interaction model within the generalized linear mixed
model. The arm-based model has several advantages over the
contrast-based model: ﬁrst, the arm-based approach uses the
exact likelihoods to model noncontinuous data, whereas the
contrast-based approach needs to transform noncontinuous data
into continuous one by means of some approximate formula
[12,24–26]. Our smoking cessation example showed that such a
transformation may yield biases in the treatment effect and
inconsistency evaluation, when event rates were low in some
treatments. Second, as long as treatment arms are independent,
no adjustment of data dependency is required for multiarm trials
in arm-based models. Contrast-based model, however, needs to
take into account the data dependency within multiarm trials in
the data analysis [12,24,25], and this is not straightforward for
most software packages [26,27]. We also demonstrate that thefact that some statistical software commands can remove redun-
dant collinear variables is very useful for specifying the incon-
sistency parameters in a network meta-analysis involving many
designs and treatments, whereas it could be a very tedious task
to locate estimable inconsistency parameter in contrast-based
models. Third, when heterogeneity variances are different across
treatments within the network, the number of parameters to be
estimated in the arm-based model is much fewer than that in the
contrast-based model. Moreover, the standard implementation of
contrast-based model requires data augmentation for studies
without the global reference treatment and continuity correction
for those with zero events. The covariances between different
treatment contrasts also need to be introduced into the data
manually. This not only requires additional efforts in data
preparation but is also prone to introducing errors during data
manipulation; furthermore, this yields bias in the estimation.
One issue with the design-by-treatment interaction is the
interpretation of main treatment effects. Recently, random effect
models have been proposed for the design-by-treatment inter-
action model by treating designs as random effect instead of ﬁxed
effects [28,29]. Treating designs as random effect is an attractive
idea, as the interpretation of the main effects becomes the
average treatment effects with the adjustment of design-by-
treatment inconsistency [12]. Most network meta-analyses, how-
ever, may not have sufﬁcient number of study designs and the
number of studies within each design to obtain a robust estima-
tion for random effect variance of designs [30]. This phenomenon
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 1 2 0 – 1 1 2 5 1125was also noted by a recent article on modeling the designs as
random effect using multilevel modeling [29], whereas another
study that proposed a Bayesian approach noted that variance
component estimation was sensitive to speciﬁcation of the prior
[28]. We therefore agree that treating the design-by-treatment as
ﬁxed or random effects has its own merits and both should be
considered in application [28].
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